The EP 2.9.8 tablet crushing strength test — formally European Pharmacopoeia 2.9.8 Resistance to Crushing of Tablets — is the mandatory compendial method in the European Union and 30+ Council of Europe signatory territories for measuring the force required to fracture a tablet by diametral compression. The chapter specifies a sample size of n = 10 tablets, requires reporting in newtons (N) as mean and standard deviation, and obligates traceable equipment calibration. Any tablet released to a European, UK (post-Brexit, via MHRA adopting Ph. Eur.), Swiss, or EEA market must be tested against EP 2.9.8 or an equivalent that has been justified to the regulator. This guide covers the full chapter content, the equipment specifications it implies, the test procedure in detail, and the decision framework for dual-compliance with USP <1217> — the standard multi-region strategy for global tablet manufacturers.

EP 2.9.8 Overview: Scope, Applicability and Regulatory Context

The European Pharmacopoeia is published by the European Directorate for the Quality of Medicines & HealthCare (EDQM), under the Council of Europe. The Ph. Eur. is legally binding in all EU and EEA member states, the United Kingdom, Switzerland, Turkey, and 30+ other observer/signatory countries — directly or through national pharmacopeia adoption. EP general chapters in the 2.9.x series cover physical and physicochemical methods; 2.9.8 specifically addresses tablet mechanical strength.

Scope of EP 2.9.8

The chapter applies to uncoated and coated tablets where a measurement of mechanical strength is required. The scope explicitly includes round, oblong, caplet, and biconvex tablets. Chewable tablets, orodispersible tablets, and film-coated tablets are in scope; sublingual and effervescent tablets are in scope when hardness is a specification attribute.

Regulatory trigger

A tablet product falls under EP 2.9.8 whenever:

The product monograph (general or individual) in the Ph. Eur. references 2.9.8.
The MA (Marketing Authorisation) dossier submitted to the EMA, MHRA, Swissmedic, or national regulator cites 2.9.8 in the specification.
The CMC/quality module of a Variation or post-approval change references tablet hardness as a release attribute.

Unlike USP <1217> which is informational (above 1000), EP 2.9.8 is a General Method — mandatory when invoked, with no "informational" loophole. An EU-market batch released without a compliant 2.9.8 record is a regulatory failure.

Companion chapters

EP 2.9.8 is typically run alongside:

EP 2.9.7 Friability of Uncoated Tablets (harmonized with USP <1216>)
EP 2.9.1 Disintegration of Tablets and Capsules (harmonized with USP <701>)
EP 2.9.5 Uniformity of Mass of Single-Dose Preparations
EP 2.9.40 Uniformity of Dosage Units (harmonized with USP <905>)

Relationship to ICH Q4B Annex 5

ICH Q4B Annex 5 addresses the interchangeability of USP <1217>, EP 2.9.8, and JP 6.09. The annex confirms the three chapters are partially harmonized — the measurement principle and core method are equivalent, but sample size and reporting format differ. A single n = 10 dataset reported in both individual and mean ± SD formats satisfies both USP <1217> and EP 2.9.8; dual-compliance is operationally straightforward with the right instrument and software.

Reading the Chapter — Key Technical Provisions

EP 2.9.8 is short and operationally clear. The provisions with direct impact on instrument selection and SOP writing are:

Definition

The chapter defines resistance to crushing as the force needed to cause a tablet to break by applying the force in a direction perpendicular to the diameter of the tablet. The force is applied via two opposing flat jaws, one of which moves at a controlled rate while the other is stationary.

Apparatus

Two jaws facing each other, flat and polished; one is fixed, the other moves at a controlled rate.
The jaws must be perfectly parallel throughout the test; non-deformable during the force application.
The instrument must apply force in a constant rate (or a constantly increasing rate) and measure the maximum force at the point of tablet fracture.
The instrument must be calibrated — the chapter refers to calibration against a known mass or force standard.

Sample

10 tablets are tested. The chapter is explicit: the mean and standard deviation are calculated from these 10 results.
Tablets must be oriented consistently: if the tablet is not round, the direction of force application relative to the tablet shape must be stated in the report.

Method

Place tablet between jaws.
Apply force at the specified rate until fracture.
Record the maximum force.
Repeat for each of the 10 tablets.

Expression of results

Mean and standard deviation in newtons (N).
Individual values should also be kept in the record even though only the mean ± SD is the compendial report.
Tablet shape and orientation must be stated.

Equipment Requirements Under EP 2.9.8: Jaws, Force Range & Calibration

Translating EP 2.9.8's functional provisions into concrete instrument specifications for a pharmaceutical texture analyzer:

Jaw geometry and material

EP 2.9.8 is more explicit than USP <1217> about jaw requirements. The jaws must be:

Flat across the working face (no curvature)
Polished (low friction, consistent contact — no machining marks that could create stress risers on the tablet)
Parallel — industry practice is within ±0.05 mm across the working face
Non-deformable — hardened steel (typically ≥ 60 HRC) or equivalent; the chapter disqualifies softer materials that would flex under load
Wide enough to fully span the tablet's contacting dimension (typically 25 mm or 40 mm wide jaws for standard tablets)

Force range

EP tablet specifications typically cover 30–300 N. A 500 N load cell is the standard pharmaceutical selection, providing headroom without sacrificing precision. High-hardness specialty tablets (e.g., moisture-barrier coated, bilayer, equine veterinary) may justify a 1000 N cell.

Force accuracy and resolution

Accuracy: ±0.5% of reading (better than the ±2% often cited as industry-minimum) ensures results near specification limits are not rejected because of instrument uncertainty.
Resolution: 0.01 N; required to resolve events on thin film-coated tablets and for work-of-fracture calculation.
Linearity: Across the full 0–500 N range, verified annually.

Speed / loading rate

EP 2.9.8 requires a constant rate of loading. Industry practice: 1.0–2.0 mm/s. The KHT TA-30 controls speed across 0.001–40 mm/s with ±1% accuracy, well within the tolerance needed for 2.9.8.

Data acquisition rate

Not stated in the chapter, but operational necessity: ≥ 200 Hz, preferably ≥ 500 Hz to capture the peak fracture force accurately. Under-sampling can cause peak-force under-estimation by 5–10%.

Calibration traceability

EP 2.9.8 expects calibration against known mass or force standards. EU regulators (EMA, BfArM, AIFA, ANSM, MHRA) expect ISO/IEC 17025 accredited external calibration services. Typical schedule:

Daily check before use (known-force verification spring or reference tablet)
Routine verification monthly (calibrated mass set)
Full calibration every 6–12 months (ISO/IEC 17025 service)

EU Annex 11 — the computerized-systems overlay

While EP 2.9.8 addresses the physical test, EU GMP Annex 11 governs the computerized system that produces, stores, and manages the data. Annex 11 is the European equivalent of 21 CFR Part 11: audit trail, e-signature, access control, periodic review. Any tablet released to an EU market from a computerized texture analyzer must satisfy both EP 2.9.8 (the method) and Annex 11 (the data system).

Test Procedure Step-by-Step (EP 2.9.8 HowTo)

The following is a compliance-ready procedure for EP 2.9.8. Adapt to your product monograph, lab QMS, and Annex 11 software configuration.

Pre-use verification. Confirm calibration is current (sticker and audit trail). Confirm environmental conditions: 21 ± 2 °C, 45 ± 15% RH typical. Verify no unresolved OOS events in the audit trail.
User authentication. Log in under your own user ID (Annex 11 §12). Confirm role permissions.
Install flat parallel tablet jaws. Hardened, polished, non-deformable. Verify parallelism (feeler gauge or optical flat within manufacturer specification).
Load cell selection. 500 N for most EP monographs. Confirm load-cell serial number is the one recorded in the method (software interlock).
Load the EP 2.9.8 SOP-locked method. Parameters: test speed 1.0 or 2.0 mm/s; return speed 10 mm/s; trigger force 0.05 N; break-detection by 40% force drop from peak; data acquisition 500 Hz; reporting units newtons; statistics mean ± SD; n = 10.
Sample preparation. Equilibrate 10 tablets to lab conditions. Visually inspect; reject chipped, cracked, laminated, or out-of-specification-appearance tablets. Record lot number and batch ID.
Load tablet #1. Position on lower jaw. For oblong/caplet: apply force across the minor axis. For round biconvex: flat band parallel to jaws. For scored tablets: score line perpendicular to applied force. Record orientation in the report.
Execute the test. Upper jaw descends at the fixed rate. Software captures peak force.
Post-test inspection. Confirm clean diametral fracture. Flag any abnormal break pattern (lamination, multiple peaks, crumble). Run OOS investigation if pattern is systematic.
Repeat for tablets #2 through #10. Total n = 10 per the chapter. Do not substitute tablets mid-test without OOS justification.
Compute statistics. Mean in N; standard deviation in N; minimum and maximum; orientation notes per tablet.
Operator e-signature. Annex 11 §14 — electronic signature with operator name, date/time, and meaning (e.g., "Tested by").
Independent review. QC supervisor reviews individual force-distance curves, statistics, and audit trail. Applies e-signature "Reviewed and approved."
Compare to specification. Product monograph: acceptance typically expressed as a mean within a stated range plus an optional minimum individual-value floor.
Disposition. Pass or fail. If fail, OOS investigation per EU GMP Chapter 6 and local SOP.
Archive. Raw data, processed results, operator signatures, audit trail retained per retention schedule.

EP 2.9.8 vs. USP 1217: Key Differences and Dual-Compliance Strategy

The single most common question from multi-region tablet manufacturers: can one method serve both the US and EU markets? Answer: yes, with the right protocol design.

Direct comparison

Attribute	EP 2.9.8	USP <1217>
Chapter status	Mandatory general method	Informational chapter (above 1000)
Sample size	n = 10 (mandatory)	n = 6 typical (chapter silent; monograph may specify)
Jaw geometry	Flat, polished, parallel, non-deformable — explicit	Flat, parallel — explicit; material not explicit
Loading rate	Constant rate (not numerical)	Constant rate (not numerical); 1–2 mm/s industry norm
Reported value	Mean ± SD in newtons (mandatory)	Individual values plus mean (typical); monograph may specify
Orientation documentation	Required	Recommended
Instrument calibration	Against known mass/force standard	Per USP <1058>
Harmonization	Partial (ICH Q4B Annex 5)	Partial (ICH Q4B Annex 5)
Data system	EU GMP Annex 11	21 CFR Part 11

Dual-compliance protocol (multi-region release)

A single SOP and single dataset can cover both markets with these rules:

Sample size = 10. The EP n = 10 is the binding constraint; 10 also satisfies any USP monograph with n = 6 or n = 10 requirement.
Report in both formats. Keep individual values for USP; compute and report mean ± SD for EP. The KHT TA-30 reporting module toggles between formats or outputs both simultaneously.
Jaws to the stricter specification. Use polished hardened-steel flat parallel jaws meeting EP's explicit material requirement — this automatically satisfies USP <1217>.
Speed fixed and documented. 1.0 or 2.0 mm/s; record the exact value in the method.
Data system to the stricter specification. Configure software to satisfy both 21 CFR Part 11 (US) and EU Annex 11. Audit trail, e-signature, access control, system validation — these overlap almost perfectly between the two rules.
Calibration traceability. ISO/IEC 17025 accredited service; traceable to SI. Acceptable to both.
Method validation per ICH Q2(R2). Applicable to both FDA and EMA submissions.

When not to use a single dual-compliance protocol

Products intended only for JP 6.09 registration — the Japanese Pharmacopoeia is not fully harmonized and may use kgf reporting; consult the dossier.
Ancient monographs specifying legacy units (e.g., kiloponds) — update the specification as part of the dossier lifecycle.
Pediatric specifications with unusual force ranges — use the appropriate load cell.

Equipment Requirements per Standard (summary table)

Requirement	EP 2.9.8 specification	KHT TA-30 native capability
Jaw flatness and parallelism	Flat, parallel, non-deformable, polished	Hardened steel (≥ 60 HRC), polished, ±0.05 mm parallelism
Force capacity	≥ 300 N (specification range typical 30–300 N)	500 N standard; 5 / 50 / 1000 N options
Force accuracy	Calibrated against traceable standard	±0.5% of reading, NIST/UKAS-traceable
Speed constancy	Constant rate	±1% across 0.001–40 mm/s
Data acquisition	Adequate to capture peak	≥ 500 Hz native
Reporting	Mean ± SD in N	N, kgf, kp; mean ± SD default
Calibration traceability	ISO/IEC 17025 preferred	Available at purchase and annually
Annex 11 / 21 CFR Part 11	Required for computerized system	Native, no paid upgrade

KHT TA-30 EP 2.9.8 Compliance Documentation Checklist

Flat, polished, hardened-steel tablet jaws — ship standard; EP-explicit material and geometry requirements met.
500 N standard load cell — covers the full EP monograph hardness range with headroom.
NIST/UKAS-traceable calibration — purchase-time certificate plus annual recalibration service.
EP 2.9.8 method template pre-loaded — n = 10, mean ± SD, newton units.
USP <1217> method template pre-loaded — for dual-compliance workflow.
JP 6.09 method template pre-loaded — kgf or N reporting toggle.
Annex 11 + 21 CFR Part 11 software — audit trail, e-signature, access control, periodic review support. Standard, not a paid upgrade.
IQ/OQ/PQ validation package — delivered with every instrument at no additional cost.
SOP lock-down — method parameters cannot be altered by routine QC operators.
Batch reporting — PDF and CSV export with operator, reviewer, and approver signatures.
Electronic archiving — data records retained per FDA/EMA retention requirements; export to LIMS via REST API.
User access control — configurable roles; site administrator defines privilege tiers.
Change control — software version history logged; validation impact flagged on updates.

EP 2.9.8 Resistance to Crushing of Tablets: Full Compliance Guide